Effect of neuroleptics and of potential new antipsychotic agents (MJ 13859-1 and MJ 13980-1) on a monkey model of tardive dyskinesia.
Two adult female cebus apella monkeys with persistent tardive dyskinesia (TD) were given acute i.m. injections of reference neuroleptics (chlorpromazine, haloperidol, thioridazine, and clozapine) or of potential new antipsychotic agents (MJ 13859-1 and MJ 13980-1). The drugs were assessed for their ability to modify TD symptoms or to produce acute neurologic reactions. Effects of three doses of MJ 13859-1 administered orally were also examined. At the doses used, thioridazine and clozapine had little or no effect. Chlorpromazine, haloperidol, MJ 13859-1 and MJ 13980-1 reduced or abolished TD and concomitantly produced hypokinesia, akinesia, mask expression, trembling, and reduced response to stimuli. Haloperidol also produced a mildly abnormal posture. In addition to the above effects, MJ 13859-1 also produced "slow motion" movement, sustained bizarre postures, sudden falls, and episodes of severe rigidity with trembling.
Kovacic
B
B
Ruffing
D
D
Stanley
M
M
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002428:Cebus; D002746:Chlorpromazine / Q000627:therapeutic use; D003024:Clozapine / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D009043:Motor Activity / Q000187:drug effects; D011187:Posture; D013141:Spiro Compounds / Q000627:therapeutic use*; D013881:Thioridazine / Q000627:therapeutic use
D014150:Antipsychotic Agents; D013141:Spiro Compounds; C042709:tiospirone; C048478:MJ 13980-1; D003024:Clozapine; D006220:Haloperidol; D013881:Thioridazine; D002746:Chlorpromazine